Diffuse Midline Glioma, H3 K27-Altered

Status: draft · Last updated 2026-11-18 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • DMG, H3 K27-altered = midline location and loss of H3K27me3. It is always WHO grade 4, whatever the histology .
  • Routes to the alteration: H3.3 or H3.1 K27M, EZHIP overexpression, or EGFR. In children, H3.3 does worse than H3.1 (median 10.1 vs 14.2 months) .
  • Children's DMGs are mostly pontine, with median OS about 12 months. Adults' are thalamic or spinal and do better .
  • Thalamic DMG: major debulking was associated with longer survival (18.5 vs 11.4 months) in HERBY. Leptomeningeal spread predicts worse outcome .
  • Always obtain tissue (biopsy or resection), and image the whole neuraxis.
  • ONC201 (dordaviprone): 20% response in recurrent H3 K27M DMG (pontine and spinal tumors excluded; mostly adults). It is the first approved systemic agent, though the evidence is debated .

Landmark papers

  • Mackay et al., Cancer Cell 2017: an integrated molecular meta-analysis of more than 1,000 pediatric high-grade gliomas and DIPGs. It defined the histone-mutant subgroups and their partner mutations .
  • ONC201 integrated analysis (Arrillaga-Romany et al., J Clin Oncol 2024): 50 patients (46 adults) with recurrent H3 K27M DMG, excluding pontine and spinal tumors, with an objective response rate of 20%. It led to the first approved systemic therapy for DMG .

Diffuse midline glioma (DMG), H3 K27-altered is a WHO 2021 tumor type defined by a diffuse glial tumor in a midline location with the molecular H3 K27 alteration, rather than by histological grade .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:diffuse_midline_glioma:519878a756e9de57© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Midsagittal brain and cervical cord mapping pontine, thalamic and spinal diffuse midline glioma with other midline sites and a bithalamic coronal inset; H3.3 K27M, H3.1 K27M (H3.2 rare), EZHIP and EGFR routes converging on loss of H3K27me3; and coronal thalamic tumor with a stereotactic biopsy trajectory or a transcortical debulking corridor(A) MIDLINE SITESthalamus (unilateral)other midline: midbrain,cerebellum, hypothalamuspons: most commonin childrenspinal cord (cervicalintramedullary)bithalamic variant(coronal)(B) MOLECULAR ROUTES TO ONE PHENOTYPEH3.3 K27M(H3F3A)H3.1 K27M(HIST1H3B/C; H3.2 rare)EZHIPoverexpressionEGFRalterationloss of H3K27me3PRC2 / EZH2 inhibiteddiffuse midlineglioma, H3 K27-altered(C) THALAMIC DMG: BIOPSY OR DEBULKINGStereotactic biopsydiagnosis and molecular profileTranscortical debulkingresectable exophytic orunithalamic tumor
Diffuse midline glioma. (a) Midsagittal and coronal map of midline sites: pons (most common in children), thalamus (unilateral or bithalamic), spinal cord, and less often the brainstem elsewhere, cerebellum or hypothalamus. (b) Molecular routes to H3 K27 alteration: K27M mutation in H3.3 (H3F3A), H3.1 (HIST1H3B/C) or rarely H3.2, EZHIP overexpression, or EGFR alteration, all converging on loss of H3K27 trimethylation. (c) Thalamic DMG: stereotactic biopsy trajectory versus debulking corridor. Not to scale.

Definition and molecular subtypes

Sites and outcomes

Role of the neurosurgeon

Treatment

Related topics

References

  1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  2. Rodriguez D, Calmon R, Aliaga ES, et al. MRI and molecular characterization of pediatric high-grade midline thalamic gliomas: the HERBY phase II trial. Radiology 2022;304(1):174–182. doi:10.1148/radiol.211464. PMID 35412366. verified
  3. Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017. PMID 28966033. verified
  4. Vuong HG, Ngo TNM, Le HT, et al. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. J Neurooncol 2022;158(3):405–412. doi:10.1007/s11060-022-04027-2. PMID 35606633. verified
  5. Sim Y, McClelland AC, Choi K, et al. A comprehensive multicenter analysis of clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma in adults. J Neurosurg 2025;142(5):1307–1318. doi:10.3171/2024.8.JNS241180. PMID 39793011. verified
  6. Arrillaga-Romany I, Gardner SL, Odia Y, et al. ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol 2024;42(13):1542–1552. doi:10.1200/JCO.23.01134. PMID 38335473. verified
  7. Khasraw M, Dun MD, Arrillaga-Romany I, et al. Point/counterpoint: dordaviprone for diffuse midline glioma—a landmark approval or a premature step? Neuro Oncol 2026;28(8):1829–1839. doi:10.1093/neuonc/noag117. PMID 42172613. verified

Verification (2026-11-18):

Caveats: